•  
  •  
 

Abstract

Commercial air travel exposes passengers to hypobaric hypoxia, reduced barometric pressure, and limited access to emergency medical support. While these physiologic changes are well tolerated by healthy travelers, individuals with chronic respiratory diseases often have reduced ventilatory or gas-exchange reserve, placing them at higher risk for in-flight hypoxemia, symptom exacerbation, and barotrauma. Respiratory problems account for approximately 12% of in-flight medical events, and nearly one-quarter of affected passengers require hospital evaluation after landing, underscoring the clinical importance of appropriate pre-flight screening.

This review summarizes current evidence on the impact of cabin altitude on oxygenation, the typical symptoms and physiologic responses observed in patients with chronic respiratory disorders, and the utility of screening tools such as resting oxygen saturation, six-minute walk testing, arterial blood gas analysis, and hypoxia altitude simulation testing. Practical guidance is provided on determining the need for in-flight supplemental oxygen, optimizing oxygen flow rates, and navigating airline requirements for portable oxygen concentrators.

Disease-specific considerations are outlined for COPD, asthma, interstitial lung disease, pneumothorax-prone conditions, pleural disease, post-bronchoscopy patients, pulmonary hypertension, obstructive sleep apnea, lung transplant recipients, and lung cancer. Although many of these patients are at measurable risk for altitude-related physiologic stress, the majority can travel safely when appropriately evaluated and prepared. By integrating individualized physiologic assessment with targeted oxygen strategies and condition-specific precautions, clinicians can support safe and confident air travel for passengers with chronic respiratory disease.

DOI

10.55729/2000-9666.1628

Share

COinS